GLORIA

GEOMAR Library Ocean Research Information Access

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    World journal of surgery 10 (1986), S. 361-368 
    ISSN: 1432-2323
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Résumé Deux cent trente-neuf transplantations précédées de transfusions de sang de donneur spécifique (DSTs) ont été effectuées de 1978 à 1984 à l'Université de Californie, San Francisco (UCSF). Les résultats de cette expérience démontrent que la DSTs se solde par une survie de la greffe à long terme excellente chez les paires non apparentés haplotype-1 ainsi que chez les paires apparentés haplotype-0 mais au cours d'une expérience plus limitée. Ces résultats sont comparables à ceux observés avec des transplants de parents HLA identiques. L'administration d'Imuran® au cours du protocole DSTs semble diminuer la sensibilisation au sang du donneur chez les malades insensibilisés qui subissent une première transplantation. Ce fait encourage la DST et la transplantation chez les sujets de ce groupe. La majorité des malades qui dans le passé ne pouvaient bénéficier de la transplantation en raison d'un cross match B à chaud positif après DST peuvent maintenant être transplantés avec succès en employant l'analyse de flux cytométrique de façon à éliminer l'activité antigénique anti-classe I de faible amplitude auparavant indetectable. Le protocole DST par lui même n'apparaît pas susceptible d'exclure la transplantation consécutive d'un organe de cadavre chez les sujets sensibilisés au sang du donneur. Les résultats préliminaires du traitement par la cyclosporin chez les paires de “donneur-receveur” vivants apparentés de type haplotype-1 sont rapportés: le taux de survie de la greffe à 1 an est identique à celui obtenu avec la transplantation d'organes de cadavre. En résumé les effets immunologiques à long terme de la DSTs ont été confirmés. Les indications et les considérations concernant l'emploi optimum de la DSTs, grâce à cette étude apparaissent plus clairement définies.
    Abstract: Resumen Se han desarrollado 239 transplantes luego de transfusiones sanguíneas específicas del donante (DSTs) desde 1978 hasta 1984 en la Universidad de California en San Francisco (UCSF). Los resultados de esta experiencia muestran que DST provee una excelente sobrevida a largo plazo del injerto en parejas desiguales en 1-haplotipo, y excelente sobrevida del injerto también ha sido obtenida en una limitada experiencia de igualdad de 0-haplotipo. Estos resultados son comparables a aquellos logrados con transplantes familiares concomitantes con HLA idéntico. En pacientes no sensibilizados sometidos a un primer transplante, el cubrimiento con Imuran® durante la administracion de DST efectivamente parece disminuír la sensibilización dependiente de DST a la sangre donante; esto fomenta el uso temprano de DST y transplante en este grupo de pacientes. La mayor parte de los pacientes anteriormente excluídos de transplante debido a un cruce B-tibio positivo post-DST pueden ser ahora exitosamente transplantados con el uso de análisis de flujo de citometría para detectar bajos nivelés, previamente no detectables, de actividad de antígeno anti-class I. El protocolo DST por sí mismo no parece impedir el transplante cadavérico subsecuente en pacientes sensibilizados a la sangre de su donante por el procedimiento DST. Resultados preliminares de tratamiento con ciclosporina en recipientes de transplante familiar iguales en 1-haplotipo son reportados con una tasa de sobrevida del injerto a un ano muy similar a aquella obtenida luego de transplante cadavérico en este mismo centra. Para resumir, el efecto inmunológico a largo plazo de DST ha sido confirmado y las indicaciones y consideraciones para el uso óptimo del protocolo de DST parecen estar mas claramente definidas.
    Notes: Abstract Two-hundred thirty-nine transplants have been performed following donor-specific blood transfusions (DSTs) from 1978 through 1984 at the University of California, San Francisco (UCSF). The results of this experience show that DST provides excellent long-term graft survival in 1-haplotype mismatched pairs. Excellent graft survival has also been obtained in a limited 0-haplotype matched experience. These results are comparable to those achieved with concurrent HLA-identical sibling transplants. Azathioprine coverage during DST administration does appear to decrease DST sensitization to the blood donor in unsensitized patients undergoing a first transplant, encouraging early DST and transplantation in this group. The majority of patients formerly excluded from transplantation because of a post-DST positive B-warm crossmatch can now be successfully transplanted with the use of flow cytometry analysis to rule out previously undetectable low levels of anti-class I antigen activity. The DST protocol by itself does not appear to preclude subsequent cadaveric transplantation in patients sensitized to their blood donor by the DST procedure. Preliminary results of cyclosporin treatment in 1-haplotype matched living-related donor-recipient pairs is reported with a 1-year graft survival rate that is similar to that obtained following cadaveric transplantation at this same center. In summary, the long-term immunologic effect of DST has been confirmed, and the indications and considerations for the optimum use of the DST protocol appear to be more clearly defined.
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-198X
    Keywords: Renal transplantation ; Transfusions ; Cyclosporine
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract In patients treated with conventional immunosuppression (azathioprine and prednisone) after renal transplantation, there is a beneficial effect of pre-transplant blood transfusions on graft survival; in patients treated with cyclosporine, this effect may be lost. In 66 children who received living-related donor transplants after donor-specific transfusions (DST) and were treated with azathioprine-prednisone in our center, 1- and 5-year graft survival rates were 99% and 77% respectively. These rates were similar to those reported for children who did not receive DST but were treated with cyclosporine in other centers. There were 634 adult and pediatric recipients of cadaver transplants in our center who were treated with cyclosporine and prednisone (non-sequential therapy,n=89) or antilymphoblast globulin, azathioprine preduisone, and cyclosporin (sequential therapy,n=545). When all patients were considered, graft survival rates were higher in transfused than in non-transfused patients at 3–5 years, but in the sequential therapy group, there were no differences in graft survival rates between transfused and non-transfused patients. The results suggest that transfusions do not improve cadaver graft survival in patients receiving optimal cyclosporine therapy and that equally good related donor graft survival can be achieved with DST and conventional immunosuppression or no DST and cyclosporine.
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Electronic Resource
    Electronic Resource
    Springer
    Pediatric nephrology 6 (1992), S. 402-402 
    ISSN: 1432-198X
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    ISSN: 1432-198X
    Keywords: Renal transplants ; Live donors ; Cadaveric donors ; Maintenance therapy ; Rehospitalization ; Rejection
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract This report of the North American Pediatric Transplant Cooperative Study summarizes data contributed by 57 participating centers on 754 children with 761 transplants from 1 January 1989 to 16 February 1989. Data collection was initiated in October 1987 and follow-up of all patients is ongoing. Transplant frequency increased with age; 24% of the patients were less than 5 years, with 7% being under 2 years. Common frequent diagnoses were: aplastic/dysplastic kidneys (18%), obstructive uropathy (16%), and focal segmental glomerulosclerosis (12%). Preemptive transplant, i.e., transplantation without prior maintenance dialysis, was performed in 21% of the patients. Dialytic modalities pretransplant were peritoneal dialysis in 42% and hemodialysis in 25%. Bilateral nephrectomy was reported in 29%. Live-donor sources accounted for 42% of the transplants. Among cadaveric donors, 41% of the donors were under 11 years old. During the first post-transplant month, maintenance therapy was used similarly for live-donor and cadaver source transplants, with prednisone, cyclosporine, and azathioprine used in 93%, 83%, and 81%, respectively. Triple therapy with prednisone, cyclosporine, and azathioprine was used in 78%, 75%, and 75% of functioning cadaver source transplants at 6 months, 12 months, and 18 months as opposed to 60%, 63%, and 54% for live-donor procedures, with single-drug therapy being uncommon. Rehospitalization during months 1–5 occurred in 62% of the patients, with treatment of rejection and infection being the main causes. Additionally, 9% were hospitalized for hypertension. During months 6–12 and 12–17, 30% and 28% of the patients with functioning grafts were rehospitalized. Times to first rejection differed significantly for cadaver and live-donor transplants. The median time to the first rejection was 36 days for cadaver transplants and 156 days for live-donor transplants. Overall, 57% of treated rejections were completely reversible although the complete reversal rate decreased to 37% for four or more rejections. One hundred and fifty-two graft failures had occurred at the time of writing, with a 1-year graft survival estimate of 0.88 for live-donor and 0.71 for cadaver source transplants. In addition to donor source, recipient age is a significant prognostic factor for graft survival. Among cadaver donors, decreasing donor age is associated with a decreasing probability of graft survival. Thirty-five deaths have occurred; 16 attributed to infection and 19 to other causes. The current 1-year survival estimate is 0.94. There have been 9 malignancies.
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...